HIV, Viral Hepatitis, STD, and TB Quality Measures

Find information on quality measures that are available to help measure and track the quality of HIV, STD, viral hepatitis and TB-related health care services. Where applicable, their use in public and select private quality measurement programs is also indicated.

Index
Quality Measures Overview

Introduction to Quality Measures

Quality measures, which can also be referred to as Clinical Quality Measures (CQMs) and electronic Clinical Quality Measures (eCQMs), are tools that help measure or quantify healthcare processes, outcomes, patient perceptions, and organizational structure and/or systems that are associated with the ability to provide high-quality health care. Measurement is a step towards improving health care quality, and quality measures help drive that improvement through a consistent and accountable approach. Please access the CMS Quality Measuresexternal icon webpage for more information.

Select Quality Reporting and Payment Programs

Quality measures are used within a wide variety of quality reporting, accreditation, and payment programs and initiatives. Programs and associated measure sets frequently used to evaluate the quality of care provided by cliniciansexternal icon, health plans, and states include some of the following:

Quality Measure Summary Tables
Summary Table Details

A Summary Table is available for HIV, viral hepatitis, STD, and TB related measures. Each table includes the following:

  • Measure Name: Lists the name of the measure as it appears in the quality program(s)
  • Brief Description: Describes the population and activity that the measure is monitoring
  • NQF ID: Provides the ID in the table if the measure is endorsed by the National Quality Forum
  • eCQM ID: Provides the number if the measure is also available as an eCQMexternal icon
  • Steward: Entity that created the quality measure and manages periodic updates. The stewards included in the summary tables are the following:
    • American Academy of Dermatology (AAD)
    • American College of Rheumatology (ACR)
    • American Gastroenterological Association (AGA)
    • Centers for Disease Control and Prevention (CDC)
    • Health Resources and Services Administration (HRSA)
    • National Committee for Quality Assurance (NCQA)
    • Physician Consortium for Performance Improvement (PCPI)
  • Programs Currently Using: Lists some of the quality programs that use the quality measure

HIV

HIV Quality Measure Summary Tables
Measure Name Brief Description NQF ID eCQM ID Steward Programs Currently Using
HIV Screening Percentage of patients 15-65 years of age who have been tested for HIV within that age range CMS349 CDC MIPS Programexternal icon
Medicaid Promoting Interoperability Programexternal icon
HIV/AIDS: Sexually Transmitted Diseases – Screening for Chlamydia, Gonorrhea, and Syphilis Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia, gonorrhea, and syphilis screenings were performed at least once since the diagnosis of HIV infection 0409 NCQA MIPS Programexternal icon
HIV Medical Visit Frequency Percentage of patients, regardless of age with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period, with a minimum of 60 days between medical visits 2079 HRSA MIPS Programexternal icon
HIV Viral Load Suppression The percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year 2082 HRSA MIPS Programexternal icon
Medicaid Adult Core Setexternal icon

Viral Hepatitis

Viral Hepatitis
Quality Measure Summary Tables
Measure Name Brief Description NQF ID eCQM ID Steward Programs Currently Using
Childhood Immunization Status Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three Haemophilus influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday 0038 CMS117 NCQA MIPS Programexternal icon
Medicaid Promoting Interoperability Programexternal icon
Medicaid Child Core Setexternal icon
HEDISexternal icon
QHP QRSpdf iconexternal icon
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users Percentage of patients, regardless of age, who are active injection drug users who received screening for HCV infection within the 12-month reporting period PCPI MIPS Programexternal icon
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis, OR birthdate in the years 1945-1965 who received one-time screening for hepatitis C virus infection 3059 PCPI MIPS Programexternal icon
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options Percentage of patients aged 18 years and older with a diagnosis of hepatitis C with whom a physician or other qualified healthcare professional reviewed the range of treatment options appropriate to their genotype and demonstrated a shared decision-making approach with the patient. To meet the measure, there must be documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment AGA MIPS Programexternal icon
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma at least once within the 12-month submission period AGA MIPS Programexternal icon

Sexually Transmitted Diseases

Sexually Transmitted Diseases Quality Measure Summary Tables
Measure Name Brief Description NQF ID eCQM ID Steward Programs Currently Using
Immunizations for Adolescents The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday 1407 NCQA MIPS Programexternal icon
Medicaid Child Core Setexternal icon
HEDISexternal icon
QHP QRSpdf iconexternal icon
Chlamydia Screening in Women Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period 0033 CMS153 NCQA MIPS Programexternal icon
Medicaid Promoting Interoperability Programexternal icon
Medicaid Adult Core Setexternal icon
Medicaid Child Core Setexternal icon
HEDISexternal icon
QHP QRSpdf iconexternal icon
HIV/AIDS: Sexually Transmitted Diseases – Screening for Chlamydia, Gonorrhea, and Syphilis Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia, gonorrhea, and syphilis screenings were performed at least once since the diagnosis of HIV infection 0409 NCQA MIPS Programexternal icon

Tuberculosis

Tuberculosis Quality Measure Summary Tables
Measure Name Brief Description NQF ID eCQM ID Steward Programs Currently Using
Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier Percentage of patients, regardless of age, with psoriasis, psoriatic arthritis and rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test AAD MIPS Programexternal icon
Rheumatoid Arthritis (RA): Tuberculosis Screening Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis who have documentation of a tuberculosis screening performed and results interpreted within 12 months prior to receiving a first course of therapy using a biologic disease-modifying anti-rheumatic drug ACR MIPS Programexternal icon
Page last reviewed: August 18, 2020